NCT06180356 2026-04-22
ANALLISA
MedSIR
Phase 2 Recruiting
Clinical Trials
10 trialsNCT05021562 2026-04-13
A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice
Takeda
Completed
NCT05183984 2026-04-13
NIRVANA-1
ARCAGY/ GINECO GROUP
Phase 2 Recruiting
NCT06915025 2026-04-13
OVATION-3
Imunon
Phase 3 Recruiting
NCT05335993 2026-04-03
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
CanariaBio Inc.
Phase 2 Active not recruiting
NCT05198804 2026-03-18
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1/2 Completed
NCT06412120 2026-03-16
Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
University of Miami
Phase 4 Recruiting
NCT03586661 2026-03-11
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT02655016 2026-03-10
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Tesaro, Inc.
Phase 3 Active not recruiting
NCT06433219 2026-02-18
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
EMD Serono
Phase 2 Active not recruiting